

REVIEW ARTICLE

Julie R. Ingelfinger, M.D., *Editor*

Vestibular Schwannomas

Matthew L. Carlson, M.D., and Michael J. Link, M.D.

VESTIBULAR SCHWANNOMAS ACCOUNT FOR 8% OF ALL INTRACRANIAL tumors and are the most common neoplasm of the cerebellopontine angle in adults. These tumors derive from myelinating Schwann cells of the vestibular division of the vestibulocochlear (eighth cranial) nerve. The term “vestibular schwannoma” is preferred over the historical misnomer “acoustic neuroma.” Though vestibular schwannomas are often considered rare, recent epidemiologic trends reveal a lifetime prevalence exceeding 1 case among 500 persons.¹ The unpredictable clinical behavior of these tumors and limited high-level evidence, plus several associated quality-of-life factors, render current management controversial. Furthermore, management varies substantially within the United States and globally.²⁻⁴

Several developments have transformed the diagnostic and therapeutic landscape of the disease. Widespread access to sensitive neurodiagnostic imaging has led to a notable rise in the detection of vestibular schwannomas^{5,6}; an increasing proportion of cases are diagnosed, often incidentally, when the tumor is small and the patient is at an advanced age^{6,7}; and there has been a shift toward conservative management strategies that prioritize preservation of neurologic function over cure.⁸ This review focuses on sporadic unilateral vestibular schwannomas, which account for more than 95% of cases. Less commonly, vestibular schwannomas develop in the context of tumor-predisposing genetic disorders such as neurofibromatosis type 2 and schwannomatosis.^{9,10}

CURRENT EPIDEMIOLOGIC FEATURES

The observed increase in the incidence of vestibular schwannomas and the shifting demographic characteristics of affected patients are mainly due to greater access to enhanced diagnostics that increase detection, as opposed to a true biologic shift.^{1,6,7,11} From the early 1900s through the 1970s, the incidence of vestibular schwannomas remained static, since patients presented with large tumors that had grown over a period of years without being detected.¹² From a historical incidence of 1 case per 100,000 person-years circa 1970, current incidence rates range from 3 to 5 cases per 100,000 person-years, with sustained increases even over the most recent decade.^{6,7} This rise has been most dramatic among persons over the age of 70 years, for whom reported incidence rates now approach 20 cases per 100,000 person-years.⁶ Today, cases are commonly diagnosed when patients are in the sixth or seventh decade of life, with tumors that are just millimeters in the greatest diameter.^{6,7}

The inflection in disease incidence corresponds to increasingly widespread access to contrast-enhanced magnetic resonance imaging (MRI), along with more stringent adoption of screening protocols for asymmetric hearing loss. Analysis of prospective data from Denmark’s national registry, spanning four decades,

From the Departments of Otolaryngology–Head and Neck Surgery and Neurologic Surgery, Mayo Clinic, Rochester, MN. Address reprint requests to Dr. Carlson at the Department of Otolaryngology–Head and Neck Surgery, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, or at carlson.matthew@mayo.edu.

This article was updated on April 8, 2021, at NEJM.org.

N Engl J Med 2021;384:1335-48.

DOI: 10.1056/NEJMra2020394

Copyright © 2021 Massachusetts Medical Society.

showed that the average age at diagnosis increased from 49 to 60 years, the mean tumor size decreased from 2.8 cm to 0.7 cm, and the severity of hearing loss at diagnosis was reduced.⁷ Moreover, in regions with widespread access to MRI, population-based data suggest that up to 25% of all new cases are diagnosed incidentally during imaging that was obtained for unrelated indications (e.g., headache).⁶ However, improved detection alone may not fully account for the increase in incidence witnessed in recent years.¹¹ Several groups have suggested that environmental exposures, such as cell phone use or long-term noise exposure may increase the risk of tumorigenesis; however, large case-control studies have failed to substantiate these associations.^{13,14} Therefore, apart from exposure to ionizing radiation, there is no consensus on exposures that increase the risk of vestibular schwannoma.¹⁵

An important ramification of increased disease detection is a potential for overtreatment, which could result in unnecessary complications and health care expenditures. Many patients, who just decades ago would have lived out their lives without having their tumors detected, are now receiving treatment.^{1,16} Though the proportion of cases initially managed with a wait-and-scan strategy is higher than ever before, paradoxically, the total number of vestibular schwannomas per population that are treated with irradiation and microsurgery is probably greater today than in prior decades (see Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).¹⁶ Nevertheless, a growing proportion of patients now undergo active monitoring of the tumor with serial imaging, signifying a transition in clinical care from up-front microsurgical resection, which epitomized treatment in earlier eras, to management of chronic disease.¹

DISEASE PRESENTATION

The spectrum of disease presentations, symptoms of progression, and treatment-associated morbidity are best understood in the context of the surrounding microanatomy (Fig. 1). The most common presenting symptoms encompass ipsilateral sensorineural hearing loss in more than 90% of patients,¹⁷ dizziness or imbalance

in up to 61%,^{17,18} and asymmetric tinnitus in 55%.¹⁹ Hearing loss is often subtle initially and may first become apparent when the patient is using a telephone or lying in bed with the contralateral ear covered. Over time, many people have increasing difficulty with sound localization and speech comprehension in the presence of background noise, which results from the loss of binaural hearing. The character and severity of tinnitus vary. Tinnitus is thought to result from cochlear deafferentation and cortical maladaptation — a mechanism akin to deafferentation pain, as seen in the phantom limb syndrome.²⁰ Thus, even in cases of profound hearing loss or a severed cochlear nerve from microsurgery, tinnitus may persist. Though vestibular schwannomas arise from the vestibular nerves and objective loss of vestibular function is common on balance testing, symptoms of vertigo and continuous dizziness occur in only about 8% and 3% of cases, respectively.¹⁸ This discrepancy presumably reflects the slow progression of vestibular loss associated with indolent tumor growth, which affords the opportunity for central compensation.

Patients with large tumors that compress the brain stem and cerebellum may have hypesthesia in a trigeminal distribution, secondary trigeminal neuralgia, cerebellar dysmetria and ataxia, or slowly progressive hydrocephalus without alteration of consciousness. Even large tumors generally do not result in clinically apparent facial-nerve, trigeminal motor, or lower cranial-nerve dysfunction, although all these disorders may occur on occasion. If such findings are present, alternative diagnoses should be considered, such as schwannomas originating from other nerves (e.g., facial-nerve schwannoma), meningiomas, metastases from primary tumors at other sites, or malignant peripheral-nerve sheath tumors that develop new or secondarily within preexisting schwannomas, either spontaneously or after radiation treatment. In addition, several disease variants, including macrocystic and hemorrhagic vestibular schwannomas, may have a more aggressive course (Fig. S2).

There is a limited association between tumor size and the severity of hearing loss, tinnitus, or dizziness at diagnosis, and symptom progression is not strongly correlated with tumor growth.^{17,21}




Figure 1. Microanatomy and Structures Affected by Vestibular Schwannomas.

Panel A (top portion) shows the relevant microanatomy of the posterior fossa. Panel A (bottom portion) and Panel B show the effect of tumor growth on adjacent cranial nerves (CN), the brain stem, and the cerebellum. Vestibular schwannomas characteristically arise within the internal auditory canal (IAC), from one of the two vestibular divisions of the vestibulocochlear nerve. Coursing ventrally to the vestibulocochlear nerve is the facial nerve, which conveys efferent motor fibers that are primarily responsible for mimetic facial movement. AICA denotes anterior inferior cerebellar artery, EAC external auditory canal, and PICA posterior inferior cerebellar artery.

These observations provide critical guidance for a wait-and-scan approach: worsening audiovestibular symptoms are not reliable barometers of tumor growth, and serial imaging studies should be obtained at regular intervals, regardless of symptoms. Furthermore, in contrast to symptoms related to mass effect in the posterior fossa, which often improve with tumor removal (e.g., trigeminal neuralgia), sensorineural hearing loss and vestibular hypofunction are not reversed with tumor treatment.²²

DIAGNOSTIC EVALUATION

Thin-slice, gadolinium-enhanced MRI of the head is the standard diagnostic approach for the detection of vestibular schwannomas as small as 2 mm in diameter.²³ Features seen on imaging are highly sensitive and specific, resulting in an accurate radiologic diagnosis in most cases, without the need for a confirmatory biopsy (Figs. 2 and 3).^{23,24}

The principal indications for obtaining a




Figure 2. Variations in the Size of Vestibular Schwannomas at Diagnosis.

Vestibular schwannomas show isointense signal on T1-weighted MRI sequences obtained before the administration of contrast material and avidly enhance with gadolinium administration. Depending on size, tumors may be fully confined to the internal auditory canal or may extend to varying degrees into the cerebellopontine angle. Panels A through D show small, medium, large, and giant left-sided vestibular schwannomas (arrows), respectively, on axial, contrast-enhanced, T1-weighted MRI. As a tumor grows, it expands within the confines of the internal auditory canal and exerts pressure on adjacent nerves before growing medially into the cerebellopontine angle. Larger tumors that extend into the cerebellopontine angle may compress the trigeminal nerve located cranially, the lower cranial nerves located caudally, and the brain stem and cerebellum medially. Progressive medial effacement of the pons may result in obstruction of the fourth ventricle and subsequent hydrocephalus. Several clinical variants of vestibular schwannomas are shown in Figure S2 in the Supplementary Appendix.

screening MRI study include sudden or asymmetric sensorineural hearing loss detected through pure-tone and speech audiometry.¹⁹ With such a history, the probability of identifying a vestibular schwannoma is between 1% and 5%.^{25,26}

Though definitions of asymmetric sensorineural hearing loss vary, widely adopted protocols specify any interaural difference on pure-tone audiometry that is 10 dB or greater in two contiguous frequencies or 15 dB or greater in any




Figure 3. Radiographic Differential Diagnosis of Tumors of the Cerebellopontine Angle.

Panel A shows the typical appearance of a small, left-sided vestibular schwannoma on contrast-enhanced, T1-weighted MRI, filling the internal auditory canal and extending into the cerebellopontine angle (arrow). Meningiomas are the second most common extraaxial tumor of the cerebellopontine angle and typically show homogeneous contrast enhancement and a broad dural base, as shown in Panel B (arrow). In contrast to vestibular schwannomas, posterior fossa meningiomas involve the internal auditory canal less frequently and typically grow eccentrically to the medial canal opening. Epidermoids are the third most common tumor of the cerebellopontine angle and are isointense to surrounding cerebrospinal fluid on T1- and T2-weighted imaging, as shown in Panel C (arrow), but characteristically display diffusion restriction on non-echo-planar diffusion-weighted imaging, as shown in Panel D (arrow). Facial-nerve schwannomas can arise from any portion of the facial nerve, from the brain stem to the terminal branches innervating the facial musculature. Distinguishing a facial-nerve schwannoma, shown in Panel E (arrow), from a vestibular schwannoma in this location on the basis of imaging findings can be difficult unless there is lateral extension of the tumor to involve the facial-nerve canal (arrowhead). Cerebellopontine-angle lipomas uniquely show hyperintense signal on T1-weighted MRI before the administration of contrast material, as shown in Panel F (arrow), with loss of signal after fat suppression. Adjacent nerves and vasculature (arrowhead) commonly course through lipomas, in contrast to most other tumors in this region, which displace surrounding neurovasculature along the peripheral tumor capsule.

single frequency (Fig. S3).¹⁹ Although screening protocols for asymmetric sensorineural hearing loss have been widely adopted, the indications

for performing MRI to investigate unilateral tinnitus or asymmetric vestibular dysfunction are not well defined.¹⁹

Patients with an isolated, unilateral vestibular schwannoma who do not have other signs of neurofibromatosis type 2 and have no affected relatives generally do not need to undergo genetic testing, nor do their family members (Text S1 in the Supplementary Appendix).⁹ Neurofibromatosis type 2 is a rare autosomal dominant disorder caused by pathogenic variants within the *NF2* gene; nearly half of affected people have a positive family history, and the remaining cases result from new variants.^{9,10} Bilateral vestibular schwannomas develop in more than 90% of people with neurofibromatosis type 2, although other cranial and spinal schwannomas and meningiomas, spinal ependymomas, peripheral-nerve schwannomas, and ophthalmologic manifestations such as juvenile cataracts and retinal hamartomas may develop.¹⁰

TREATMENT

The substantial evolution in the management of vestibular schwannoma over the past century has resulted in multiple reasonable options for most patients that are associated with low expected morbidity and almost no risk of death.²⁷⁻²⁹ Treatment strategies can be divided into an observational wait-and-scan approach, irradiation, microsurgery, and a combination of these methods. Several new drug therapies that aim to halt tumor growth, including aspirin and monoclonal antibodies, have recently been explored but remain investigational.³⁰ A list of ongoing clinical trials is summarized in Table S1. To date, there is no high-level evidence indicating that one treatment approach is unequivocally superior to others.^{3,4} Instead, each strategy has a set of advantages and limitations.^{3,31} Moreover, data show that the diagnosis itself and patient-related factors affect the quality of life more than does treatment choice.³² Tumor size chiefly drives treatment recommendations; however, decision making is also guided by subtle patient- and provider-related factors.^{2,33} Referral to a specialty center offers patients with a new diagnosis an opportunity to obtain information regarding tumor management and potential treatment of problematic symptoms. In view of the variations in clinical practice among centers, obtaining more than one opinion from larger specialty groups and obtaining educational material pro-

vided by independent, national patient-support organizations are encouraged.² Table S2 lists consensus statements, guidelines, and position papers published within the past 5 years.

WAIT-AND-SCAN APPROACH

The wait-and-scan approach has gained popularity for at least two reasons: many tumors are now discovered as small masses in older people with mild symptoms; furthermore, reports over the past 15 years have documented radiographically that only 22 to 48% of tumors have shown growth (most commonly defined as an increase of ≥ 2 mm in diameter) (Text S2) during a mean of 2.6 to 7.3 years of follow-up.^{5-7,34-36} The most consistent predictor of future growth during an observational strategy is larger tumor size at diagnosis.³⁴⁻³⁶ Typically, tumors that have a maximal diameter of less than 1.5 cm in the cerebello-pontine angle are considered for a wait-and-scan approach.

Imaging and audiologic evaluation are commonly performed 6 months after the diagnostic MRI in order to identify a fast-growing tumor or a more aggressive process mimicking a vestibular schwannoma.³¹ If there is no growth at 6 months, imaging and hearing assessments are performed annually thereafter until year 5, when many specialists advocate every-other-year assessments.^{23,31} Given the unpredictable nature of tumor growth and the capacity for saltatory or delayed growth, lifelong follow-up is recommended.^{31,37} If growth is definitively confirmed, most patients receive a recommendation to undergo radiosurgery or microsurgery. To minimize the cost of ongoing tumor surveillance and the risk of adverse events related to contrast material, several groups have transitioned to the use of thin-slice, heavily T2-weighted magnetic resonance cisternography without contrast material, which has a high degree of accuracy and inter-rater reliability.²⁴

Progression of hearing loss, with or without radiographic evidence of tumor growth, is expected during observation with serial imaging.^{38,39} The mechanisms driving hearing loss in patients with untreated tumors are incompletely understood but potentially include neurovascular compression of the cochlear nerve or labyrinthine artery, impaired cerebrospinal fluid circulation, and tumor-mediated inflammation.⁴⁰ Analysis of

population-based data from Denmark showed that 334 of 636 patients had useful hearing at diagnosis, with a speech discrimination score of more than 70% (indicating that 70% percent of words were repeated back correctly by the patient), but after 10 years of observation, only 31% retained hearing above this threshold.³⁹ Notably, 88% of patients who started with a speech discrimination score of 100% still had a score of more than 70% at 10 years, suggesting that excellent speech comprehension at diagnosis portends favorable long-term hearing outcomes.

An important concern about an observational strategy is attrition. In a French study involving 386 patients, 16% were lost to follow-up in the first year of a wait-and-scan strategy.⁴¹ Unfortunately, since symptom progression is not strongly correlated with tumor growth²¹ and since the growth rate is highly variable, patients who are lost to follow-up are at increased risk for the development of a large tumor, with an associated increase in the risk of a poor outcome with eventual treatment.

RADIOSURGERY

Stereotactic radiosurgery typically involves the use of highly conformal radiation, defined as radiation delivered in 1 to 5 fractions to an image-defined target, with maximal sparing of the surrounding tissue. Gamma-knife radiosurgery is one type of conformal radiation. Gamma-knife treatment consists of 192 cobalt-60 sources arranged concentrically to deliver an ovoid isocenter of radiation. Treatment typically incorporates a stereotactic head frame and thin-slice, non-contrast-enhanced computed tomography and contrast-enhanced axial MRI to stereotactically target the tumor in three-dimensional space (Fig. 4). Linear accelerator-based platforms are also used by many centers. Most of these systems involve a single, collimated radiation beam with a gantry that rotates around the patient, creating a focused arc of radiation that stereotactically targets the lesion of interest. Generally, the entire procedure is performed in an outpatient setting, with no activity restrictions for the patient after radiosurgery.


The aim of radiosurgery for a schwannoma is to prevent tumor growth; treatment does not confer a radiographic cure, and the tumor will

be visible indefinitely on MRI. Transient tumor enlargement within the first 3 years after radiosurgery is common, although variable tumor shrinkage eventually occurs in more than half of treated cases.⁴² After radiosurgery, patients undergo audiometric evaluation and MRI studies annually for the first 3 years, then every other year until 10 years, then every 5 years indefinitely.³¹ In contemporary radiosurgery series, tumor control is reported in more than 90% of cases of vestibular schwannoma at 10 years of follow-up.⁴³ Radiosurgical treatment failure is typically defined by tumor growth that persists for more than 3 years, the development of signs or symptoms associated with progressive mass effect, and rapid tumor enlargement.³¹ Salvage microsurgery is generally recommended after failed radiosurgery, although at several centers, repeat radiosurgery has been successful in select cases.⁴⁴



Patients with tumors that have a maximal diameter of less than 3.0 cm in the cerebello-pontine angle are usually considered to be candidates for radiosurgery. However, tumors that are less than 2.5 cm are preferred in order to minimize the risk of radiation-induced brainstem edema, trigeminal neuropathy or neuralgia, and hydrocephalus, as well as diminished long-term tumor control.⁴⁵ Some centers preferentially use hypofractionation or conventional multifraction delivery of stereotactic radiation, which potentially allows for the treatment of larger tumors than those for which single-fraction treatment has traditionally been considered to be safe. Single-fraction stereotactic radiosurgery, with a marginal dose of 13 Gy or less, is associated with a 1% or lower risk of permanent facial-nerve weakness and less than a 5% risk of trigeminal neuropathy, depending on the tumor volume.⁴³ The risk of a secondary cancer from radiosurgery approaches 0.02%.⁴⁶ The influence of radiosurgery on progression of hearing loss remains controversial, but many centers report rates of serviceable hearing preservation of 50 to 70% over a follow-up period of 3 to 5 years.^{38,47} Serviceable hearing designates a level of hearing that is still functionally useful, with or without a hearing aid, and is defined by a speech discrimination score of at least 50% and a pure-tone average threshold of 50 dB or less.³⁸

A General approach

- Tumors <3.0 cm in maximum cerebellopontine angle usually considered candidates
- Low-dose radiation is delivered in a single dose or multiple fractionated doses
- Radiation treatment is successful in halting tumor growth in more than 90% of cases; the tumor may shrink slightly over time but will never completely disappear



B Delivery of gamma radiation using cobalt-based systems



C Delivery of high-energy photon radiation using LINAC systems






Figure 4 (facing page). Radiosurgical Techniques for the Treatment of Vestibular Schwannomas.

Stereotactic radiosurgery delivers highly conformal radiation to an image-defined target to selectively treat the tumor and maximally spare the surrounding healthy tissue (Panel A). The gamma knife (Elekta), in its current iteration, consists of 192 cobalt-60 sources arranged concentrically to deliver a highly conformal, ovoid isocenter of radiation (Panel B). Treatment is usually performed after placement of a stereotactic head frame while the patient is under local anesthesia, with subsequent thin-slice, contrast-enhanced, axial fused MRI-computed tomographic imaging to target the tumor. Depending on pretreatment hearing status and tumor volume, the dose prescribed is usually 12 to 14 Gy at the 50% isodose line, delivered in a single fraction. The treatment plan shown (right) calls for a prescribed dose of 13 Gy delivered to the 50% isodose line. The cochlea, outlined in magenta, customarily receives varying levels of radiation, even with highly conformal planning. Most linear accelerator (LINAC)-based systems (Panel C) use a single, collimated radiation beam with a mobile gantry to create a focused arc of radiation, with frameless stereotaxis; the patient is typically immobilized with the use of a customized, soft, plastic face mask. Treatments may be given in single or multiple fractions. Pictured is the Novalis LINAC system (Panel C, top), powered by TrueBeam STx 2018 (Varian Medical Systems and Brainlab). The treatment plan (right) prescribes a dose of 12.5 Gy delivered to the 80% isodose line in a single fraction. Cyber-knife radiotherapy (Cyber-Knife, Accuray) (Panel C, bottom) involves frameless, LINAC-based radiation delivered by means of a highly maneuverable robotic arm with 6 df for movement, with real-time image guidance. The treatment plan (right) prescribes hypofractionated radiation, at a dose of 25 Gy delivered in 5 fractions to the 80% isodose line.

MICROSURGERY

Microsurgical resection can be performed on tumors of all sizes and is the treatment of choice for large tumors associated with symptomatic brain-stem compression, hydrocephalus, trigeminal neuralgia or neuropathy, or a combination of these complications.^{22,48} All procedures are performed while the patient is under general anesthesia and require the use of an operating microscope with intraoperative neural monitoring.^{48,49} A narrated video outlining the steps involved in microsurgical resection of a vestibular schwannoma and the relevant anatomy can be viewed at NEJM.org.

The three primary microsurgical approaches used to remove vestibular schwannomas are the middle fossa, translabyrinthine, and retrosigmoid approaches, each with benefits and limitations

(Fig. 5). The principal objectives are the same, regardless of the approach: maximal tumor removal with preservation of neurologic function. Intraoperative facial-nerve monitoring with electromyography is routinely used.⁴⁹ Cochlear-nerve monitoring is frequently used when hearing preservation is attempted, and monitoring of other regional cranial nerves may be incorporated for large tumors.^{31,49} Most patients are hospitalized for 2 to 4 days after the procedure and are ambulatory at the time of discharge. Exertional activity is generally restricted for 6 to 12 weeks after surgery. Fatigue and ongoing imbalance are common during early convalescence but usually improve within 3 months. Most patients undergo a baseline postoperative MRI study within the first 12 months after surgery, with periodic surveillance MRI studies thereafter; the interval between studies is based on the extent of resection and the results of early postoperative imaging.³¹ The risk of tumor recurrence after gross total resection is 0 to 2%.^{28,50}

Primary surgical risks are directly proportional to tumor size and most often are related to postoperative hearing and facial-nerve function.^{38,48} Serviceable hearing is preserved in 40 to 70% of patients with small tumors (<1.5 cm in diameter), and facial weakness is permanent in less than 10%.^{27,38,51} The probability of preserving serviceable hearing after surgery for tumors that are more than 2.5 cm is less than 5%, and the risk of permanent partial or complete facial-nerve paralysis after total resection of large tumors is approximately 50%.⁵²⁻⁵⁴ Given such risks, intentionally leaving a tumor remnant around the facial nerve and brain stem has gained popularity.⁵⁵ The risk of postoperative growth of residual tumor is proportional to the volume left behind.³¹ Overall, approximately 30% of tumors regrow to some degree after subtotal tumor resection and are usually treated with radiosurgery.^{31,56} Fortunately, the risk of other major neurovascular complications, such as permanent injury to other regional cranial nerves or perioperative stroke, is rare, even with large tumors.²⁹ The prevalence of postoperative cerebrospinal fluid leak is 9 to 13%,^{57,58} aseptic meningitis 2 to 4%,^{58,59} and culture-positive bacterial meningitis 1%.⁵⁹ Published data indicate that higher-volume centers have superior short-term outcomes, with a shorter hospital stay and lower costs.^{60,61}



A video showing vestibular schwannoma microsurgery is available at NEJM.org




Figure 5 (facing page). Microsurgical Approaches for the Treatment of Vestibular Schwannomas.

Shown are the translabyrinthine, retrosigmoid, and middle fossa microsurgical approaches for resection of vestibular schwannomas. The translabyrinthine craniotomy (Panel A) is the only approach that inherently sacrifices hearing function, since it involves drilling through the inner ear. This surgical approach encompasses a postauricular incision, removal of bone between the ear canal and sigmoid sinus, and removal of the semicircular canals to reach the IAC and cerebellopontine angle (CPA). Advantages of this approach include a reduced need for cerebellar retraction, full access to the lateral-most extent of the IAC, and early identification of the distal facial nerve. Theoretically, a tumor of any size can be removed through this approach. At the conclusion of tumor removal, an abdominal fat graft is used to fill the bony defect to reduce the risk of postoperative cerebrospinal fluid leak. The retrosigmoid craniotomy (Panel B) is a versatile approach for select tumors that offers a wide view of the CPA and the possibility of hearing preservation. The surgery entails a curvilinear, vertically oriented occipital incision and a craniotomy positioned just posterior and inferior to the sigmoid and transverse sinuses, respectively. Once the dura is opened, the posterior lip of the IAC is removed to expose the extension of the tumor into this bony canal. Drilling is typically limited by the posterior semicircular canal and vestibule, which cannot be breached if hearing is to be preserved. As with the translabyrinthine approach, a tumor of any size can be accessed through the retrosigmoid approach. The middle fossa approach (Panel C) is typically used only for small tumors confined to the IAC or those with less than 1 cm of medial extension into the CPA, when hearing preservation is a primary goal. The approach includes a temporal incision and a craniotomy centered just above the root of the zygoma. Extradural dissection is then performed under the temporal dura, and the bone covering the IAC is removed to provide access to the tumor. The advantage of this approach is that it allows access to nearly the full length of the IAC and is associated with a relatively high rate of hearing preservation among patients with small tumors. A potential disadvantage is the need for temporal-lobe retraction and a slightly higher risk of at least temporary facial weakness, as compared with other approaches for tumors of similar size. Arrows denote the direction of access.

REHABILITATION

In most people with vestibular schwannomas, long-term facial-nerve function remains good, and there is sufficient compensation for unilateral audiovestibular deficits. However, some patients require rehabilitative intervention — most

commonly, those with long-term facial-nerve paralysis, bilateral hearing loss, or chronic dizziness or imbalance.

For people with vestibular schwannomas in whom serviceable hearing is maintained in the ipsilateral ear, observation (i.e., no additional hearing rehabilitation) or use of a conventional hearing aid is generally adequate. However, in most patients, nonserviceable hearing ultimately develops in the affected ear, resulting in impaired sound localization and difficulty understanding speech in the presence of background noise.^{62,63} If aural rehabilitation is pursued, most available options encompass technologies that route sound from the deaf ear to the ear with better hearing through surgical means (i.e., bone-conduction implants) or nonsurgical means (e.g., contralateral routing of signals [CROS] hearing aids). Cochlear implantation to restore hearing in patients with sporadic vestibular schwannomas is currently investigational. Preliminary data suggest that 50 to 85% of highly selected patients with cochlear implants are able to understand speech. However, this strategy is feasible only in patients who have a cochlear nerve that has not been critically injured by microsurgery or radiosurgery (Fig. S4).^{64,65} Despite the availability of these options, less than one third of people with vestibular schwannomas ultimately undergo trial use of a hearing device, and only approximately 20% regularly use such a device, in part because of the limitations surrounding these technologies but also because most people adequately adjust to the hearing deficit.⁶³

Severe, chronic dizziness or imbalance, with an associated risk of falling, is rarely related to disease progression or tumor treatment and generally has a multifactorial cause.¹⁸ Common conditions that may exacerbate dizziness include peripheral neuropathy, age-related loss of contralateral vestibular function, vision loss, and vestibular migraine.^{18,66} Thus, people who report substantial dizziness or imbalance should undergo a comprehensive balance assessment to accurately identify any coexisting disorders and to assess and mitigate the risk of falling. The mammalian peripheral vestibular system has limited regenerative capacity. Thus, balance therapy is the therapeutic mainstay for people who

have troublesome symptoms related to chronic vestibular hypofunction.⁶⁷

Permanent facial-nerve paralysis is uncommon overall, but the risk approaches 50% among patients with large tumors who have undergone microsurgical resection.^{53,54} Flaccid paralysis and eye dryness are primary concerns in the early postoperative period. Although many of the stigmata of facial-nerve injury can be electively managed, incomplete eye closure must be aggressively treated to reduce the risk of exposure keratopathy, commonly manifested as blurred vision, ocular pain, and redness. Eye lubricants and moisture chambers generally provide adequate protection in the early postoperative period. However, referral to an ophthalmologist for upper-eyelid weight placement, punctal plugs, or tarsorrhaphy should be considered if longer-term paralysis is anticipated or ophthalmologic complications appear. The rate and extent of facial-nerve recovery after microsurgery is variable. Improvement is generally greatest within 6 months after the onset of paralysis, but continued recovery can be seen for up to 18 months.⁶⁸ The management of permanent facial-nerve paralysis is complex and potentially time-sensitive. Therefore, referral to a specialty clinic should be considered for patients with severe facial-nerve paralysis who do not have improvement within the first 6 months.⁶⁸

CONCLUSIONS

With increased access to sensitive neurodiagnostic imaging, the epidemiology and management of sporadic vestibular schwannomas have evolved substantially in recent years. Today, the diagnosis is often made when tumors are very small, as well as in older patients with minimal symptoms or incidentally. Treatment algorithms have evolved to prioritize functional outcomes over a definitive cure. Microsurgery is generally preferred for the treatment of tumors that are larger than 3 cm in diameter. However, in the absence of high-level evidence to inform decision making, there are multiple reasonable treatment options for most patients with small or medium-size vestibular schwannomas, including the wait-and-scan approach, radiosurgery, and microsurgery. As such, patient preference plays a major role in shared decision making.

Dr. Carlson reports receiving grant support from Cochlear Ltd. and holding pending patents 62/346,306, PCT/US2017/035617, and WO2017213978A1 on devices and methods for treating tinnitus with the use of electrical stimulation. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank our colleagues, including Kelly D. Flemming, M.D., and John P. Marinelli, M.D., for editorial assistance with earlier versions of the manuscript, Andrew J. Goates, M.D., for editorial assistance with an earlier version of the narrated video, and Mohamed H. Khattab, M.D., Leslie A. Nussbaum, M.D., Ph.D., and Eric S. Nussbaum, M.D., for providing radiosurgery dose plans for Figure 4.

REFERENCES

- Marinelli JP, Grossardt BR, Lohse CM, Carlson ML. Prevalence of sporadic vestibular schwannoma: reconciling temporal bone, radiologic, and population-based studies. *Otol Neurotol* 2019;40:384-90.
- Carlson ML, Glasgow AE, Grossardt BR, Habermann EB, Link MJ. Does where you live influence how your vestibular schwannoma is managed? Examining geographical differences in vestibular schwannoma treatment across the United States. *J Neurooncol* 2016;129:269-79.
- Gauden A, Weir P, Hawthorne G, Kaye A. Systematic review of quality of life in the management of vestibular schwannoma. *J Clin Neurosci* 2011;18:1573-84.
- Muzevic D, Legcevic J, Splavski B, Cayé-Thomasen P. Stereotactic radiotherapy for vestibular schwannoma. *Cochrane Database Syst Rev* 2014;12:CD009897.
- Tos M, Stangerup S-E, Cayé-Thomasen P, Tos T, Thomsen J. What is the real incidence of vestibular schwannoma? *Arch Otolaryngol Head Neck Surg* 2004;130:216-20.
- Marinelli JP, Lohse CM, Carlson ML. Incidence of vestibular schwannoma over the past half-century: a population-based study of Olmsted County, Minnesota. *Otolaryngol Head Neck Surg* 2018;159:717-23.
- Reznitsky M, Petersen MMBS, West N, Stangerup S-E, Cayé-Thomasen P. Epidemiology of vestibular schwannomas — prospective 40-year data from an unselected national cohort. *Clin Epidemiol* 2019;11:981-6.
- Carlson ML, Habermann EB, Wagie AE, et al. The changing landscape of vestibular schwannoma management in the United States — a shift toward conservatism. *Otolaryngol Head Neck Surg* 2015;153:440-6.
- Mohyuddin A, Neary WJ, Wallace A, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. *J Med Genet* 2002;39:315-22.
- Smith MJ, Bowers NL, Bulman M, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. *Neurology* 2017;88:87-92.
- Marinelli JP, Lohse CM, Grossardt BR, Lane JL, Carlson ML. Rising incidence of sporadic vestibular schwannoma: true biological shift versus simply greater detection. *Otol Neurotol* 2020;41:813-47.
- Ramsden RT. The bloody angle: 100 years of acoustic neuroma surgery. *J R Soc Med* 1995;88:464P-468P.
- Pettersson D, Mathiesen T, Prochazka M, et al. Long-term mobile phone use and acoustic neuroma risk. *Epidemiology* 2014;25:233-41.
- Cao Z, Zhao F, Mulugeta H. Noise exposure as a risk factor for acoustic neuroma: a systematic review and meta-analysis. *Int J Audiol* 2019;58:525-32.
- Ron E, Modan B, Boice JD Jr, et al. Tumors of the brain and nervous system after radiotherapy in childhood. *N Engl J Med* 1988;319:1033-9.
- Marinelli JP, Grossardt BR, Lohse CM, Carlson ML. Is improved detection of ves-

- tibular schwannoma leading to overtreatment of the disease? *Otol Neurotol* 2019;40:847-50.
17. Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. *Neurosurgery* 1997;40:1-9.
 18. Carlson ML, Tveiten OV, Driscoll CL, et al. Long-term dizziness handicap in patients with vestibular schwannoma: a multicenter cross-sectional study. *Otolaryngol Head Neck Surg* 2014;151:1028-37.
 19. Sweeney AD, Carlson ML, Shepard NT, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on otologic and audiological screening for patients with vestibular schwannomas. *Neurosurgery* 2018;82:E29-E31.
 20. Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus. *Otolaryngol Head Neck Surg* 2014;151:Suppl: S1-S40.
 21. Patel NS, Huang AE, Dowling EM, et al. The influence of vestibular schwannoma tumor volume and growth on hearing loss. *Otolaryngol Head Neck Surg* 2020;162:530-7.
 22. Neff BA, Carlson ML, O'Byrne MM, Van Gompel JJ, Driscoll CLW, Link MJ. Trigeminal neuralgia and neuropathy in large sporadic vestibular schwannomas. *J Neurosurg* 2017;127:992-9.
 23. Dunn IF, Bi WL, Mukundan S, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the role of imaging in the diagnosis and management of patients with vestibular schwannomas. *Neurosurgery* 2018;82:E32-E34.
 24. Kim DH, Lee S, Hwang SH. Non-contrast magnetic resonance imaging for diagnosis and monitoring of vestibular schwannomas: a systematic review and meta-analysis. *Otol Neurotol* 2019;40:1126-33.
 25. Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical practice guideline: sudden hearing loss (update). *Otolaryngol Head Neck Surg* 2019;161:Suppl:S1-S45.
 26. Waterval J, Kania R, Somers T. EAONO position statement on vestibular schwannoma: imaging assessment: what are the indications for performing a screening MRI scan for a potential vestibular schwannoma? *J Int Adv Otol* 2018;14:95-9.
 27. Ansari SE, Terry C, Cohen-Gadol AA. Surgery for vestibular schwannomas: a systematic review of complications by approach. *Neurosurg Focus* 2012;33:E14.
 28. Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them. *Neurosurgery* 1997;40:11-21.
 29. Mahboubi H, Ahmed OH, Yau AY, Ahmed YC, Djalilian HR. Complications of surgery for sporadic vestibular schwannoma. *Otolaryngol Head Neck Surg* 2014;150:275-81.
 30. Van Gompel JJ, Agazzi S, Carlson ML, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on emerging therapies for the treatment of patients with vestibular schwannomas. *Neurosurgery* 2018;82:E52-E54.
 31. Carlson ML, Link MJ, Driscoll CLW, et al. Working toward consensus on sporadic vestibular schwannoma care: a modified Delphi Study. *Otol Neurotol* 2020;41(10):e1360-e1371.
 32. Carlson ML, Tveiten OV, Driscoll CL, et al. Long-term quality of life in patients with vestibular schwannoma: an international multicenter cross-sectional study comparing microsurgery, stereotactic radiosurgery, observation, and nontumor controls. *J Neurosurg* 2015;122:833-42.
 33. Carlson ML, Tveiten OV, Lund-Johansen M, Tombers NM, Lohse CM, Link MJ. Patient motivation and long-term satisfaction with treatment choice in vestibular schwannoma. *World Neurosurg* 2018;114:e1245-e1252.
 34. Lees KA, Tombers NM, Link MJ, et al. Natural history of sporadic vestibular schwannoma: a volumetric study of tumor growth. *Otolaryngol Head Neck Surg* 2018;159:535-42.
 35. Reznitsky M, Petersen MMBS, West N, Stangerup S-E, Caye-Thomasen P. The natural history of Vestibular Schwannoma growth — prospective 40-year data from an unselected national cohort. *Neuro Oncol* 2020 October 17 (Epub ahead of print).
 36. Hunter JB, Francis DO, O'Connell BP, et al. Single institutional experience with observing 564 vestibular schwannomas: factors associated with tumor growth. *Otol Neurotol* 2016;37:1630-6.
 37. Macielak RJ, Patel NS, Lees KA, et al. Delayed tumor growth in vestibular schwannoma: an argument for lifelong surveillance. *Otol Neurotol* 2019;40:1224-9.
 38. Carlson ML, Vivas EX, McCracken DJ, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on hearing preservation outcomes in patients with sporadic vestibular schwannomas. *Neurosurgery* 2018;82: E35-E39.
 39. Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J. Change in hearing during 'wait and scan' management of patients with vestibular schwannoma. *J Laryngol Otol* 2008;122:673-81.
 40. Bowen AJ, Carlson ML, Lane JI. Inner ear enhancement with delayed 3D-FLAIR MRI imaging in vestibular schwannoma. *Otol Neurotol* 2020;41:1274-9.
 41. El Bakkouri W, Kania RE, Guichard JP, Lot G, Herman P, Huy PT. Conservative management of 386 cases of unilateral vestibular schwannoma: tumor growth and consequences for treatment. *J Neurosurg* 2009;110:662-9.
 42. Breshears JD, Chang J, Molinaro AM, et al. Temporal dynamics of pseudoprogession after gamma knife radiosurgery for vestibular schwannomas — a retrospective volumetric study. *Neurosurgery* 2019;84:123-31.
 43. Johnson S, Kano H, Faramand A, et al. Long term results of primary radiosurgery for vestibular schwannomas. *J Neurooncol* 2019;145:247-55.
 44. Iorio-Morin C, Liscak R, Vladyka V, et al. Repeat stereotactic radiosurgery for progressive or recurrent vestibular schwannomas. *Neurosurgery* 2019;85:535-42.
 45. Bailo M, Boari N, Franzin A, et al. Gamma knife radiosurgery as primary treatment for large vestibular schwannomas: clinical results at long-term follow-up in a series of 59 patients. *World Neurosurg* 2016;95:487-501.
 46. Seferis C, Torrens M, Paraskevopoulou C, Psichidis G. Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. *J Neurosurg* 2014;121:Suppl:160-6.
 47. Yang I, Aranda D, Han SJ, et al. Hearing preservation after stereotactic radiosurgery for vestibular schwannoma: a systematic review. *J Clin Neurosci* 2009;16: 742-7.
 48. Hadjipanayis CG, Carlson ML, Link MJ, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on surgical resection for the treatment of patients with vestibular schwannomas. *Neurosurgery* 2018;82:E40-E43.
 49. Vivas EX, Carlson ML, Neff BA, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on intraoperative cranial nerve monitoring in vestibular schwannoma surgery. *Neurosurgery* 2018;82:E44-E46.
 50. Ahmad RARL, Sivalingam S, Topsakal V, Russo A, Taibah A, Sanna M. Rate of recurrent vestibular schwannoma after total removal via different surgical approaches. *Ann Otol Rhinol Laryngol* 2012;121:156-61.
 51. Preet K, Ong V, Sheppard JP, et al. Postoperative hearing preservation in patients undergoing retrosigmoid craniotomy for resection of vestibular schwannomas: a systematic review of 2034 patients. *Neurosurgery* 2020;86:332-42.
 52. Yates PD, Jackler RK, Satar B, Pitts LH, Oghalai JS. Is it worthwhile to attempt hearing preservation in larger acoustic neuromas? *Otol Neurotol* 2003;24:460-4.
 53. Grinblat G, Dandinarsaiah M, Braverman I, Taibah A, Lisma DG, Sanna M.

- “Large and giant vestibular schwannomas: overall outcomes and the factors influencing facial nerve function.” *Neurosurg Rev* 2020 August 29 (Epub ahead of print).
54. Gurgel RK, Dogru S, Amdur RL, Monfared A. Facial nerve outcomes after surgery for large vestibular schwannomas: do surgical approach and extent of resection matter? *Neurosurg Focus* 2012; 33:E16.
55. Monfared A, Corrales CE, Theodosopoulos PV, et al. Facial nerve outcome and tumor control rate as a function of degree of resection in treatment of large acoustic neuromas: preliminary report of the Acoustic Neuroma Subtotal Resection Study (ANSRS). *Neurosurgery* 2016;79:194-203.
56. Romiyo P, Ng E, Dejam D, et al. Radiosurgery treatment is associated with improved facial nerve preservation versus repeat resection in recurrent vestibular schwannomas. *Acta Neurochir (Wien)* 2019;161:1449-56.
57. Mangus BD, Rivas A, Yoo MJ, et al. Management of cerebrospinal fluid leaks after vestibular schwannoma surgery. *Otol Neurotol* 2011;32:1525-9.
58. Selesnick SH, Liu JC, Jen A, Newman J. The incidence of cerebrospinal fluid leak after vestibular schwannoma surgery. *Otol Neurotol* 2004;25:387-93.
59. Sanchez GB, Kaylie DM, O'Malley MR, Labadie RF, Jackson CG, Haynes DS. Chemical meningitis following cerebellopontine angle tumor surgery. *Otolaryngol Head Neck Surg* 2008;138:368-73.
60. Barker FG II, Carter BS, Ojemann RG, Jyung RW, Poe DS, McKenna MJ. Surgical excision of acoustic neuroma: patient outcome and provider caseload. *Laryngoscope* 2003;113:1332-43.
61. Hatch JL, Bauschard MJ, Nguyen SA, Lambert PR, Meyer TA, McRackan TR. Does hospital volume affect outcomes in patients undergoing vestibular schwannoma surgery? *Otol Neurotol* 2018;39:481-7.
62. Tveiten OV, Carlson ML, Link MJ, Lund-Johansen M. Audiovestibular handicap and quality of life in patients with vestibular schwannoma and “excellent” hearing. *Neurosurgery* 2017;80:386-92.
63. Drusin MA, Lubor B, Losenegger T, Selesnick S. Trends in hearing rehabilitation use among vestibular schwannoma patients. *Laryngoscope* 2020;130:1558-64.
64. Urban MJ, Moore DM, Kwarta K, et al. Ipsilateral cochlear implantation in the presence of observed and irradiated vestibular schwannomas. *Ann Otol Rhinol Laryngol* 2020;129:1229-38.
65. Wick CC, Butler MJ, Yeager LH, et al. Cochlear implant outcomes following vestibular schwannoma resection: systematic review. *Otol Neurotol* 2020;41:1190-7.
66. Jahn K. The aging vestibular system: dizziness and imbalance in the elderly. *Adv Otorhinolaryngol* 2019;82:143-9.
67. Taylor RR, Folia A, Paredes U, et al. Regenerating hair cells in vestibular sensory epithelia from humans. *Elife* 2018;7:e34817.
68. Rivas A, Boahene KD, Bravo HC, Tan M, Tamargo RJ, Francis HW. A model for early prediction of facial nerve recovery after vestibular schwannoma surgery. *Otol Neurotol* 2011;32:826-33.

Copyright © 2021 Massachusetts Medical Society.

IMAGES IN CLINICAL MEDICINE

The *Journal* welcomes consideration of new submissions for Images in Clinical Medicine. Instructions for authors and procedures for submissions can be found on the *Journal's* website at NEJM.org. At the discretion of the editor, images that are accepted for publication may appear in the print version of the *Journal*, the electronic version, or both.